![Dora Hammerl](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Dora Hammerl
Sociétés | Poste | Début | Fin |
---|---|---|---|
Pan Cancer T
![]() Pan Cancer T BiotechnologyHealth Technology Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023. | Directeur Technique/Scientifique/R&D | 01/09/2020 | - |
Fondateur | 01/09/2020 | - |
Historique de carrière de Dora Hammerl
Statistiques
Internationale
Pays-Bas | 2 |
Opérationnelle
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Pan Cancer T
![]() Pan Cancer T BiotechnologyHealth Technology Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023. | Health Technology |
- Bourse
- Insiders
- Dora Hammerl
- Expérience